The 9 most recent market catalysts affecting $SPTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 14, 2026
Corporate Catalyst
Neutral
Impact 65
Canaccord Genuity Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $28
Canaccord Genuity's initiation of coverage on Seaport Therapeutics (SPTX) with a 'Buy' rating and a $28 price target is a significant event for the company. Analyst coverage, espec…
Oct 8, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a 'Buy' rating and a $50 price target for Seaport Therapeutics (SPTX). This action signals that the analyst's investme…
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a 'Buy' rating and a $50 price target for Seaport Therapeutics (SPTX). This action signals continued confidence from a pro…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 75
Seaport Therapeutics Reports Phase 1 Results; GlyphAllo At 375 mg Meets Primary Endpoint With No Driving Impairment; 250 mg Dose Also Achieves Key Secondary Endpoint
Seaport Therapeutics reported positive Phase 1 results for GlyphAllo, demonstrating that the drug did not impair next-morning driving performance at either 375 mg or 250 mg doses. …
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 65
Jones Trading Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $32
Jones Trading analyst Justin Walsh has initiated coverage on Seaport Therapeutics (SPTX) with a 'Buy' rating and a $32 price target. This event is significant for SPTX as new analy…
Aug 20, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a 'Buy' rating and a $50 price target for Seaport Therapeutics (SPTX). This action signals continued confidence from a…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a 'Buy' rating and a $50 price target for Seaport Therapeutics (SPTX). This is a routine but positive development, as …
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 95
Seaport Therapeutics Q2 EPS $(1.78) Misses $(0.65) Estimate
Seaport Therapeutics (SPTX) announced Q2 losses of $(1.78) per share, which is a substantial miss compared to the analyst consensus estimate of $(0.65). This 173.85% miss indicates…
Jul 15, 2026
Corporate Catalyst
Neutral
Impact 75
HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50
HC Wainwright & Co. initiating coverage on Seaport Therapeutics with a 'Buy' rating and a $50 price target is a strong positive signal for the company. This analyst endorsement can…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.